Discovery of a potent, selective, and tumor-suppressing antibody antagonist of adenosine A2A receptor
PLOS ONE · 05.06.2024 · 19 (6) · e0301223
DOI: 10.1371/journal.pone.0301223 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, online erschienen am 05.06.2024. Verfasst von Linya Wang und 16 weiteren Autor:innen. Beteiligte Einrichtung: Twist Bioscience, San Francisco, California, United States of America. Hauptthemen laut MEDLINE: Receptor, Adenosine A2A, Adenosine A2 Receptor Antagonists. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
New immune checkpoints are emerging in a bid to improve response rates to immunotherapeutic drugs. The adenosine A 2A receptor (A 2A R) has been proposed as a target for immunotherapeutic development due to its participation in immunosuppression of the tumor microenvironment. Blockade of A 2A R could restore tumor immunity and, consequently, improve patient outcomes. Here, we describe the discovery of a potent, selective, and tumor-suppressing antibody antagonist of human A 2A R (hA 2A R) by phage display. We constructed and screened four single-chain variable fragment (scFv) libraries—two synthetic and two immunized—against hA 2A R and antagonist-stabilized hA 2A R. After biopanning and ELISA screening, scFv hits were reformatted to human IgG and triaged in a series of cellular binding and functional assays to identify a lead candidate. Lead candidate TB206-001 displayed nanomolar binding of hA 2A R-overexpressing HEK293 cells; cross-reactivity with mouse and cynomolgus A 2A R but not human A 1 , A 2B , or A 3 receptors; functional antagonism of hA 2A R in hA 2A R-overexpressing HEK293 cells and peripheral blood mononuclear cells (PBMCs); and tumor-suppressing activity in colon tumor-bearing HuCD34-NCG mice. Given its therapeutic properties, TB206-001 is a good candidate for incorporation into next-generation bispecific immunotherapeutics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Twist Bioscience, San Francisco, California, United States of America.
- Gilead, Foster City, California, United States of America.
- Slingshot, Los Angeles, California, United States of America.
- Nurix Therapeutics, San Francisco, California, United States of America.
- Sartorius, Fremont, California, United States of America.
ORCID-Profile: Aaron K Sato
Zitieren
APA
Wang, L., Garg, P., Chan, K. Y., Yuan, T. Z., Lujan Hernandez, A. G., Han, Z., Peterson, S. M., Tuscano, E., Safavi, C., Kwan, E., Villalta, M., Mathur, M., Lai, J., Axelrod, F., Souders, C. A., Emery, C., & Sato, A. K. (2024). Discovery of a potent, selective, and tumor-suppressing antibody antagonist of adenosine A2A receptor. PLOS ONE, 19(6), e0301223. https://doi.org/10.1371/journal.pone.0301223
Vancouver
Wang L, Garg P, Chan KY, Yuan TZ, Lujan Hernandez AG, Han Z, et al. Discovery of a potent, selective, and tumor-suppressing antibody antagonist of adenosine A2A receptor. PLOS ONE. 2024;19(6):e0301223. doi:10.1371/journal.pone.0301223
BibTeX
@article{Wang2024,
author = {Wang, Linya and Garg, Pankaj and Chan, Kara Y and Yuan, Tom Z and Lujan Hernandez, Ana G and Han, Zhen and Peterson, Sean M and Tuscano, Emily and Safavi, Crystal and Kwan, Eric and Villalta, Mouna and Mathur, Melina and Lai, Joyce and Axelrod, Fumiko and Souders, Colby A and Emery, Chloe and Sato, Aaron K},
title = {Discovery of a potent, selective, and tumor-suppressing antibody antagonist of adenosine A2A receptor},
journal = {PLOS ONE},
year = {2024},
volume = {19},
number = {6},
pages = {e0301223},
doi = {10.1371/journal.pone.0301223}
}
EUVIMED